Your session is about to expire
← Back to Search
Pacing
Pacing Techniques for Post-TAVR Heart Block
N/A
Recruiting
Led By Ali Keramati, MD
Research Sponsored by Main Line Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 18 months
Awards & highlights
No Placebo-Only Group
Summary
This trial tests if switching to left bundle branch pacing can improve heart function better than traditional RV pacing after TAVR.
Who is the study for?
This trial is for adults over 18 who've had a transcatheter aortic valve replacement (TAVR) in the last two weeks, have high-grade heart block or cardiomyopathy but still have an ejection fraction over 50%. They must be getting their first pacemaker and not need more complex devices like biventricular pacers. Pregnant women, those with mechanical heart valves, previous heart transplants, or life expectancy under two years are excluded.
What is being tested?
The study compares two types of pacemaker placements after TAVR: one group gets left bundle branch area pacing first then switches to right ventricular septal pacing; the other does this in reverse order. The goal is to see which method better supports heart function using ultrasound measures of how well the left ventricle pumps blood.
What are the potential side effects?
While specific side effects aren't listed here, generally speaking, potential risks from pacemaker implantation can include infection at the implant site, bleeding or bruising, lead displacement causing poor pacing function or need for reoperation.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 18 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~18 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in global longitudinal strain (GLS%)
Change in left ventricular ejection fraction (LVEF%)
Composite of left bundle branch area pacing lead septal myocardial or coronary artery perforation, lead dislodgment, and repeat procedures related to left bundle branch area lead implantation
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Group BExperimental Treatment1 Intervention
Group II: Group AExperimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
Main Line HealthLead Sponsor
21 Previous Clinical Trials
6,843 Total Patients Enrolled
MedtronicIndustry Sponsor
619 Previous Clinical Trials
764,042 Total Patients Enrolled
13 Trials studying Aortic Valve Stenosis
6,151 Patients Enrolled for Aortic Valve Stenosis
Sharpe-Strumia Research FoundationOTHER
7 Previous Clinical Trials
843 Total Patients Enrolled
Ali Keramati, MDPrincipal InvestigatorLankenau Heart Institute
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have had a heart transplant.I am 18 years old or older.I had a TAVR procedure within the last four weeks.My heart's pumping ability is above 50%, or at least 45% if estimated.I have a heart rhythm problem that affects my heartbeat.
Research Study Groups:
This trial has the following groups:- Group 1: Group A
- Group 2: Group B
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.